Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women.
OBJECTIVE
This study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis.


METHODS
This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (< or = 85 years old) who were naïve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at 3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate treatment were also assessed.


RESULTS
Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients were comparable in the BMF versus no-BMF arms (92.6%vs. 96.0%, P = 0.16); overall, serum CTX levels were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients.


CONCLUSIONS
The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence, but increased treatment satisfaction.
Kung
Annie Wai-Chee
AW
Rachman
Ichramsjah A
IA
Adam
John M F
JM
Roeshadi
Djoko
D
Torralba
Tito
T
Navarra
Sandra
S
Gamilla
Zayda
Z
Cañete
Arthur
A
de la Rosa
Miles
M
Tsai
KehSung
K
Lin
Hsiao-Yi
HY
Soong
Yung Kuei
YK
Lan
Joung-Liang
JL
Hsu
Horng-Chaung
HC
Tu
Shih-Te
ST
Lin
Ruey-Mo
RM
Yuktanandana
Pongsak
P
Songpatanasilp
Thawee
T
Ngarmukos
Srihatach
S
Soontrapa
Sugree
S
Soontrapa
Suppasin
S
Rojanasthien
Sattaya
S
Luevitoonvechkij
Sirichai
S
Leerapan
Taninnit
T
Albert
Adelin
A
Vanbelle
Sophie
S
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D015415:Biomarkers / Q000097:blood*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism* / Q000517:prevention & control*; D010349:Patient Compliance; D017060:Patient Satisfaction
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid